Investors Targeted in Park Ha Biological Technology Securities Lawsuit

The lawsuit claims that Park Ha Biological Technology was the centerpiece of a fraudulent stock promotion scheme. According to the filing, the company allegedly utilized social media misinformation and impersonated financial professionals to drive interest in its stock. Furthermore, the complaint asserts that the company’s IPO was intentionally designed with an extremely low public float to facilitate market manipulation, while failing to disclose these artificial trading conditions to the public.

Investors seeking to serve as lead plaintiff in the action must file a motion with the court no later than September 28, 2026. Participation in the lawsuit does not require out-of-pocket expenses, as the firm operates on a contingency fee basis. While no class has been certified yet, those who purchased securities during the specified window retain the right to select their own counsel or remain absent class members. Interested parties can contact Phillip Kim at the Rosen Law Firm for further legal details.